Menu
1-702-720-6310 info@microcapspecualtors.com

Will There be Another MJ Gold Rush this Fall?

Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential.

It seems that every fall there is a massive rush into Marijuana related companies.  This could be due to a multitude of reasons.  For investors the most important fact, should be the that interest in MJ related companies has spiked in the fall for several years running.  

With the global legal cannabis market poised to eclipse $57B, there is incredible room for growth, and even a small market share could mean massive profits to companies.

These companies could reap the rewards of an MJ gold rush this fall: Nightfood Hldgs Inc. (OTCPINK: NGTF), Cronos Group Inc. (NASDAQ: CRON), and

INSYS Therapeutics, Inc. (NASDAQ: INSY)

Nightfood Hldgs Inc. (OTCPINK: NGTF)

Market Cap: $15.28M, current share price: $.36

NightFood manufactures and distributes better-for-you snacks specifically formulated to satisfy unhealthy nighttime cravings in a better, healthier, more sleep-friendly way. Future product line extensions may include formats such as NightFood cookies, NightFood ice cream, NightFood bites, and more. In addition, MJ Munchies, Inc. was recently formed as a new, wholly owned subsidiary, to exploit legally compliant opportunities in the CBD and marijuana edibles and related spaces.  The Company intends to market some of these new products under the Half-Baked™ brand name. As the legal landscape around CBD and cannabis related products continues to change and evolve, MJ Munchies will continue to explore, identify, and capitalize on opportunities clearly defined as legal.  The Company believes tremendous opportunities currently exist to launch successful and compliant products in this space, and that such opportunities will continue to grow over time.

Cronos Group Inc. (NASDAQ: CRON)

Market Cap: $1.26B, current share price: $6.99

Cronos Group Inc., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marijuana for Medical Purposes Regulations. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights.

INSYS Therapeutics, Inc . (NASDAQ: INSY)

Market Cap: $559.47M, current share price: $7.58

Insys Therapeutics, Inc., is a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi.

GW Pharmaceuticals Plc. (NASDAQ: GWPH)

Market Cap: $4.26B, current share price: $151.15

GW Pharmaceuticals plc, is a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia.

The Green Organic Dutchman Holdings Ltd. (NASDAQ: TGODF)

Market Cap: $1.01B, current share price: $4.45

The Green Organic Dutchman Holdings Ltd., through its subsidiary, The Green Organic Dutchman Ltd., operates as a cannabinoid-based research and development company in Canada. It produces organic cannabis products, including organic dried cannabis, cannabis oils and edibles, fresh cannabis, and seeds for medical applications

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.  ACR Communication, LLC has been compensated one thousand dollars cash for this article and twenty-six thousand total by Regal Consulting, LLC, for NGTF.  NGTF and Regal Consulting, LLC were given an opportunity to edit information included in this article.  This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.  ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

Search